A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Recruiting now

Conditions studied: Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease

In brief

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Key facts

Study ID

NCT07517250

Run by

Novartis Pharmaceuticals

People needed

160

Starts

2026-03-15

Expected to finish

2026-12-03

Last updated by the study team

2026-06-09

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
• Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

You may not qualify if…

• Patients Aged <2 Years (24 Months) at Index Date.

Where it is running

• Novartis — Basel, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.